Peter Ruus

1.1k total citations
13 papers, 919 citations indexed

About

Peter Ruus is a scholar working on Molecular Biology, Neurology and Biochemistry. According to data from OpenAlex, Peter Ruus has authored 13 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Neurology and 4 papers in Biochemistry. Recurrent topics in Peter Ruus's work include Alcoholism and Thiamine Deficiency (4 papers), Biochemical Acid Research Studies (4 papers) and Metabolism and Genetic Disorders (3 papers). Peter Ruus is often cited by papers focused on Alcoholism and Thiamine Deficiency (4 papers), Biochemical Acid Research Studies (4 papers) and Metabolism and Genetic Disorders (3 papers). Peter Ruus collaborates with scholars based in Germany, United States and Australia. Peter Ruus's co-authors include Róbert Hermann, Jens Teichert, Rainer Preiß, Franck Poitiers, Agnès Hincelin-Méry, Thomas Först, Christoph Kapitza, G. Dietze, E. Maerker and W. Renn and has published in prestigious journals such as Free Radical Biology and Medicine, Clinical Pharmacology & Therapeutics and Drug Metabolism and Disposition.

In The Last Decade

Peter Ruus

13 papers receiving 862 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Ruus Germany 10 393 368 317 207 133 13 919
Ametov As Russia 10 294 0.7× 199 0.5× 336 1.1× 379 1.8× 83 0.6× 149 1.1k
M Lobisch Germany 9 535 1.4× 219 0.6× 126 0.4× 477 2.3× 29 0.2× 14 1.1k
Kempei Matsuoka Japan 19 67 0.2× 386 1.0× 179 0.6× 204 1.0× 115 0.9× 40 1.4k
Katsunori Horie Japan 10 93 0.2× 248 0.7× 373 1.2× 62 0.3× 101 0.8× 14 1.4k
H J Augustin Germany 7 287 0.7× 171 0.5× 148 0.5× 137 0.7× 44 0.3× 8 649
D Hannak Germany 9 97 0.2× 162 0.4× 194 0.6× 163 0.8× 45 0.3× 19 790
Lamia Fathallah United States 13 152 0.4× 222 0.6× 149 0.5× 129 0.6× 72 0.5× 24 1.0k
Yi‐Fei Dong Japan 20 79 0.2× 320 0.9× 274 0.9× 44 0.2× 135 1.0× 27 1.2k
Ken Omata Japan 23 428 1.1× 459 1.2× 628 2.0× 27 0.1× 115 0.9× 108 1.7k
Pedro L. Prieto‐Hontoria Spain 19 440 1.1× 344 0.9× 103 0.3× 107 0.5× 68 0.5× 27 1.1k

Countries citing papers authored by Peter Ruus

Since Specialization
Citations

This map shows the geographic impact of Peter Ruus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ruus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ruus more than expected).

Fields of papers citing papers by Peter Ruus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ruus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ruus. The network helps show where Peter Ruus may publish in the future.

Co-authorship network of co-authors of Peter Ruus

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ruus. A scholar is included among the top collaborators of Peter Ruus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ruus. Peter Ruus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
Lorenz, M., et al.. (2013). Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia. Regulatory Peptides. 185. 1–8. 122 indexed citations
3.
Kapitza, Christoph, et al.. (2013). Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obesity and Metabolism. 15(7). 642–649. 161 indexed citations
4.
Teichert, Jens, et al.. (2005). Pharmacokinetics of Alpha‐Lipoic Acid in Subjects With Severe Kidney Damage and End‐Stage Renal Disease. The Journal of Clinical Pharmacology. 45(3). 313–328. 51 indexed citations
5.
Teichert, Jens, Róbert Hermann, Peter Ruus, & Rainer Preiß. (2003). Plasma Kinetics, Metabolism, and Urinary Excretion of Alpha‐Lipoic Acid following Oral Administration in Healthy Volunteers. The Journal of Clinical Pharmacology. 43(11). 1257–1267. 116 indexed citations
6.
Hermann, Róbert, Géraldine M. Ferron, Katharina Erb, et al.. (2003). Effects of age and sex on the disposition of retigabine. Clinical Pharmacology & Therapeutics. 73(1). 61–70. 43 indexed citations
7.
Jacob, Simon N., Peter Ruus, Róbert Hermann, et al.. (1999). Oral administration of rac-α-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radical Biology and Medicine. 27(3-4). 309–314. 218 indexed citations
8.
Nguyen, Nghia, Christian P. Strassburg, Qing Li, et al.. (1999). Retigabine N-Glucuronidation and Its Potential Role in Enterohepatic Circulation. Drug Metabolism and Disposition. 27(5). 605–612. 70 indexed citations
9.
Hermann, Róbert, et al.. (1998). Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers. European Journal of Pharmaceutical Sciences. 6(1). 27–37. 15 indexed citations
10.
Hermann, Róbert, Peter Ruus, Edith Schneider, & Christian de Mey. (1998). Tolerability and in vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate.. PubMed. 48(6). 663–7. 3 indexed citations
11.
Hermann, Róbert, G Niebch, Harald O. Borbe, et al.. (1996). Enantioselective pharmacokinetics and bioavailability of different racemic α-lipoic acid formulations in healthy volunteers. European Journal of Pharmaceutical Sciences. 4(3). 167–174. 93 indexed citations
12.
Schneider, Edith, G Niebch, Róbert Hermann, Peter Ruus, & Harald O. Borbe. (1995). Absolute bioavailability of flupirtine capsules drops and suppositories in man. European Journal of Clinical Pharmacology. 49. 161. 1 indexed citations
13.
Farthing, M.J.G., E M Alstead, S. M. L. Abrams, et al.. (1994). Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. Postgraduate Medical Journal. 70(823). 363–366. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ametov As Breakdown of academic impact, for papers by M Lobisch Breakdown of academic impact, for papers by Kempei Matsuoka Breakdown of academic impact, for papers by Katsunori Horie Breakdown of academic impact, for papers by H J Augustin Breakdown of academic impact, for papers by D Hannak Breakdown of academic impact, for papers by Lamia Fathallah Breakdown of academic impact, for papers by Yi‐Fei Dong Breakdown of academic impact, for papers by Ken Omata Breakdown of academic impact, for papers by Pedro L. Prieto‐Hontoria
Rankless by CCL
2026